Kordata Dynamics Closes Pre-Seed Funding

The company plans to use the funds to expand its operations and support additional research and development.

Kordata’s platform is designed to deliver fast and high-quality results, even in complex treatment areas. Its clinical trial model also uses BIOS’ AI-powered precision dosing technology, NeuroTune, which provides real-time insights into how patients respond to drugs and treatments. The system analyzes neural data from invasive and non-invasive sources to understand the body’s response to medicines better.

With an initial focus on precision neuromodulation and neural therapies, Kordata is targeting a clinical trial market with a $26 billion backlog. Its work is relevant to many conditions, including major brain disorders such as Alzheimer’s, Parkinson’s, and epilepsy, as well as drug-resistant forms of chronic diseases like cardiovascular disease, autoimmune disorders, and autonomic dysfunction.

Kordata Dynamics believes clinical research can become faster, more reliable, and easier to access. This direction was also highlighted by the FDA last month in its new initiative to support real-time monitoring of clinical trial data.

Fast and high-quality clinical trials are important for developing safe and affordable medicines. Over the past 50 years, only 5% of U.S. hospitals have taken part in clinical trials. After the pandemic, countries like China improved their ability to run trials at a national scale and are now competing for many new medical breakthroughs.

Kordata’s real-time, AI-powered approach could help the U.S. become more competitive by accelerating, improving precision, and simplifying clinical trials. It could also allow the remaining 95% of U.S. hospitals to participate in clinical research.

Bakersfield was chosen as Kordata’s first city because it fits the company’s goal of making precision medicine more accessible. California’s Central Valley supports major industries that generate 40% of the state’s GDP and has a strong data-driven culture shaped by aerospace, agriculture, and energy industries. At the same time, the region has a large patient population with limited access to advanced clinical research.

Strong government and local relationships, along with an established network of doctors, partners, and hospitals, will help Kordata quickly develop and launch its platform. The company also plans to expand this network by connecting U.S. clinicians with global experts and researchers to encourage knowledge sharing and faster innovation.

According to her, the company plans to bring these important elements into the broader clinical trial industry, where limited funding, slow innovation, and long timelines are common challenges. She said the company is committed to providing high-quality treatment options for patients while using technology and new advances to expand possibilities. She also said the team is excited to begin operations in Bakersfield.

Read More:Red River Names Mike Sang as Chief Financial Officer

Kordata Dynamics President, Dawn McCollough, has a proven 30-year track record in clinical trials, with involvement in more than 15,000 trials and the launch of 27 drugs. Also a former Executive at Biogen and Novartis, she said, “At Kordata, we enable sponsors, sites, researchers and clinicians to access the benefits of AI-powered precision medicine tools previously out of reach, helping unlock the kind of high-quality, precise data and efficiencies that drive breakthroughs.”

“Powered by BIOS’ technology, we can simplify dosing for complex medicines. We have collaborated with KVG, DNIH and MAVRK to launch Kordata Dynamics to take this further. The combination should unlock the treatments which otherwise might not come to light,” said Hewage.

“That’s an exciting development for our field, and exactly what our model is designed for,” said Emil Hewage, CEO of BIOS Health and Kordata. “The vision is for high-quality trials that recruit in 3-6 months rather than over many years, provide clear data, and enfranchise vastly more patients and clinicians in the advancement of medicine.”

About Kordata Dynamics

Kordata Dynamics is a U.S.-based clinical trial technology company that uses real-time trial execution tools and BIOS Health’s AI and neural biomarker technology to accelerate precision medicine, making it faster, smarter, and more accessible. The company simplifies the collection and analysis of large-scale health data across regional medical centers, helping make clinical trials easier, more consistent, and higher quality. Backed by Kern Venture Group, MAVRK Celestia Fund, BIOS Health, and Digital Neural Infrastructure Holdings, Kordata was built in California with a focus on global impact.

Read More:Radian CEO Rick Thornberry Announces Intent to Retire, Board Appoints Mike Weinbach as His Successor